Advertisement
Advertisement

FEMY

FEMY logo

Femasys Inc. Common Stock

0.43
USD
Sponsored
0.00
-0.28%
Apr 15, 15:59 UTC -4
Closed
exchange

After-Market

0.42

-0.01
-2.10%

FEMY Earnings Reports

Positive Surprise Ratio

FEMY beat 9 of 18 last estimates.

50%

Next Report

Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$617.61K
/
-$0.09
Implied change from Q4 25 (Revenue/ EPS)
-24.13%
/
+800.00%
Implied change from Q1 25 (Revenue/ EPS)
+80.98%
/
-60.87%

Femasys Inc. Common Stock earnings per share and revenue

On Mar 31, 2026, FEMY reported earnings of -0.01 USD per share (EPS) for Q4 25, beating the estimate of -0.08 USD, resulting in a 88.80% surprise. Revenue reached 814.00 thousand, compared to an expected 1.32 million, with a -38.38% difference. The market reacted with a -3.15% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 617.61 thousand USD, implying an increase of 800.00% EPS, and decrease of -24.13% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
logo
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
FAQ
For Q4 2025, Femasys Inc. Common Stock reported EPS of -$0.01, beating estimates by 88.8%, and revenue of $814.00K, -38.38% below expectations.
The stock price moved down -3.15%, changed from $0.50 before the earnings release to $0.48 the day after.
The next earning report is scheduled for May 07, 2026.
Based on 3 analysts, Femasys Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $617.61K for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement